Navigation Links
Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
Date:3/11/2009

Regenerative Medicine Team Put in Place to Serve Future Requirements of Stem Cell Researchers

ST. LOUIS, March 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of an online web portal that provides researchers with immediate access to its extensive portfolio of industry-leading products developed specifically for advanced stem cell research. The new portal features over 1,100 unique and highly-focused products that are expected to support every step of the stem cell research workflow - from isolation, characterization, expansion, differentiation and functional profiling to in-vitro/in-vivo tracking. In addition, a team of regenerative medicine experts has been retained to continue to identify and develop new and promising technologies in this growing area. The portal also provides access to a robust stem cell biology community and is available at http://www.sigma-aldrich.com/stemcell.

"As a leading destination for life science researchers to access deep biological information and market-leading products, Sigma's focus is to help scientists resolve complex biological questions," said Dr. Dave Smoller, president of the Company's Research Biotech business unit. "Our focus on regenerative medicine and the resulting growing line of stem cell products should help our customers develop cardiac, hematopoietic, endocrine, and neurological disease therapies."

The portal's expanding line of cutting-edge technologies for stem cell research includes the industry's most highly-validated shRNA library, the MISSION(R) RNAi portfolio, which enables gene silencing across a wide range of cellular targets. The site also features the CompoZrTM zinc finger nuclease (ZFN) reagent platform which enables researchers, for the first time, to target and precisely manipulate the genome of both differentiated cells and stem cells, resulting in cell lines or whole organisms with permanent, targeted gene deletions, insertions, or corrections. A complete line of polyclonal and monoclonal antibodies is available, including the Prestige Antibodies(R) collection, considered the industry's most highly characterized line of antibodies. StemlineTM animal serum-free media, essential to many researchers in the expansion and maturation of cell lines, is also available.

Stem cell research has the potential to benefit individuals affected by a wide range of debilitating and life threatening conditions. New approaches are expected to make it possible to reprogram differentiated somatic cells, such as fibroblasts, into stem cells which can then be used for a variety of research applications. Sigma-Aldrich provides access to a growing portfolio of specialized platforms and products to support these businesses.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 37 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich, MISSION, CompoZr, Prestige Antibodies and Stemline are trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
2. Sigma-Aldrich (NASDAQ:SIAL) Announces it Has Filed Its December 31, 2008 Form 10-K
3. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
4. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
5. Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity
6. Sigma-Aldrich Corporations 4th Quarter 2008 Earnings Conference Call
7. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
8. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
9. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
10. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
11. Sigma-Aldrich to Present at the 19th Annual Citi Chemicals Conference Tuesday, December 2, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):